Literature DB >> 12567308

Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus.

Carmen Martinez-Sierra1, Ana Arizcorreta, Fernando Díaz, Rafael Roldán, Leopoldo Martín-Herrera, Eugenio Pérez-Guzmán, José A Girón-González.   

Abstract

To evaluate the factors associated with the evolution of chronic hepatitis C in human immunodeficiency virus (HIV)-infected patients, a cross-sectional analysis of 41 HIV-infected patients with chronic hepatitis C (known as "HIV-HCV [hepatitis C virus]-coinfected patients") and a control group of patients with chronic hepatitis C who did not have HIV infection (known as "non-HIV-infected patients") was performed. The association of histological variables with demographic parameters, HCV load and genotype, HIV load, CD4(+) T cell count, and response to highly active antiretroviral therapy (HAART) was evaluated. HIV-HCV-coinfected patients showed a significantly higher HCV load, more-advanced fibrosis, and a higher liver fibrosis progression rate (FPR) than did non-HIV-infected patients. A high HCV load and a low CD4(+) T cell count were associated with a higher FPR. The immune response induced by HAART did not influence this progression. In conclusion, HIV-HCV-infected patients, mainly such patients with a high HCV load and an immunodepressed state, have a higher FPR. An independent effect of the immune response to HAART was not evident.

Entities:  

Mesh:

Year:  2003        PMID: 12567308     DOI: 10.1086/367643

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  50 in total

Review 1.  Opioids and HIV/HCV infection.

Authors:  Xu Wang; Ting Zhang; Wen-Zhe Ho
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-14       Impact factor: 4.147

Review 2.  Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes.

Authors:  Yaron Rotman; T Jake Liang
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

3.  Transient elastography: a non-invasive tool for assessing liver fibrosis in HIV/HCV patients.

Authors:  Valentina Li Vecchi; Maurizio Soresi; Claudia Colomba; Giovanni Mazzola; Pietro Colletti; Maurizio Mineo; Paola Di Carlo; Emanuele La Spada; Giovanni Vizzini; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2010-11-07       Impact factor: 5.742

4.  A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease.

Authors:  Michael L Washburn; Moses T Bility; Liguo Zhang; Grigoriy I Kovalev; Adam Buntzman; Jeffery A Frelinger; Walter Barry; Alexander Ploss; Charles M Rice; Lishan Su
Journal:  Gastroenterology       Date:  2011-01-13       Impact factor: 22.682

Review 5.  HCV/ HIV co-infection: time to re-evaluate the role of HIV in the liver?

Authors:  J T Blackard; K E Sherman
Journal:  J Viral Hepat       Date:  2008-01-17       Impact factor: 3.728

6.  Rapid development of advanced liver fibrosis after acquisition of hepatitis C infection during primary HIV infection.

Authors:  Anu Osinusi; David Kleiner; Brad Wood; Michael Polis; Henry Masur; Shyam Kottilil
Journal:  AIDS Patient Care STDS       Date:  2009-06       Impact factor: 5.078

7.  The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010.

Authors:  Marc-Arthur Loko; Dominique Salmon; Patrizia Carrieri; Maria Winnock; Marion Mora; Laurence Merchadou; Stéphanie Gillet; Elodie Pambrun; Jean Delaune; Marc-Antoine Valantin; Isabelle Poizot-Martin; Didier Neau; Philippe Bonnard; Eric Rosenthal; Karl Barange; Philippe Morlat; Karine Lacombe; Anne Gervais; François Rouges; Alain Bicart See; Caroline Lascoux-Combe; Daniel Vittecoq; Cécile Goujard; Claudine Duvivier; Bruno Spire; Jacques Izopet; Philippe Sogni; Lawrence Serfaty; Yves Benhamou; Firouzé Bani-Sadr; François Dabis
Journal:  BMC Infect Dis       Date:  2010-10-22       Impact factor: 3.090

8.  Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin.

Authors:  Tess Petersen; Yu-Jin Lee; Anu Osinusi; Valerianna K Amorosa; Crystal Wang; Minhee Kang; Roy Matining; Xiao Zhang; Diana Dou; Triin Umbleja; Shyam Kottilil; Marion G Peters
Journal:  AIDS Res Hum Retroviruses       Date:  2016-03-14       Impact factor: 2.205

Review 9.  HIV and co-infections.

Authors:  Christina C Chang; Megan Crane; Jingling Zhou; Michael Mina; Jeffrey J Post; Barbara A Cameron; Andrew R Lloyd; Anthony Jaworowski; Martyn A French; Sharon R Lewin
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

Review 10.  Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV.

Authors:  Christine E MacBrayne; Jennifer J Kiser
Journal:  Clin Infect Dis       Date:  2016-07-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.